Anti-LY66F/ LY6G6F/ C6orf21 monoclonal antibody

Anti-LY66F/ LY6G6F/ C6orf21 antibody for FACS & in-vivo assay

Target products collectionGo to LY6G6F/LY6G6F products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0779-Ab-1/ GM-Tg-hg-MP0779-Ab-2Anti-Human LY6G6F monoclonal antibodyHuman
GM-Tg-rg-MP0779-Ab-1/ GM-Tg-rg-MP0779-Ab-2Anti-Rat LY6G6F monoclonal antibodyRat
GM-Tg-mg-MP0779-Ab-1/ GM-Tg-mg-MP0779-Ab-2Anti-Mouse LY6G6F monoclonal antibodyMouse
GM-Tg-cynog-MP0779-Ab-1/ GM-Tg-cynog-MP0779-Ab-2Anti-Cynomolgus/ Rhesus macaque LY6G6F monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0779-Ab-1/ GM-Tg-felg-MP0779-Ab-2Anti-Feline LY6G6F monoclonal antibodyFeline
GM-Tg-cang-MP0779-Ab-1/ GM-Tg-cang-MP0779-Ab-2Anti-Canine LY6G6F monoclonal antibodyCanine
GM-Tg-bovg-MP0779-Ab-1/ GM-Tg-bovg-MP0779-Ab-2Anti-Bovine LY6G6F monoclonal antibodyBovine
GM-Tg-equg-MP0779-Ab-1/ GM-Tg-equg-MP0779-Ab-2Anti-Equine LY6G6F monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0779-Ab-1/ GM-Tg-hg-MP0779-Ab-2; GM-Tg-rg-MP0779-Ab-1/ GM-Tg-rg-MP0779-Ab-2;
GM-Tg-mg-MP0779-Ab-1/ GM-Tg-mg-MP0779-Ab-2; GM-Tg-cynog-MP0779-Ab-1/ GM-Tg-cynog-MP0779-Ab-2;
GM-Tg-felg-MP0779-Ab-1/ GM-Tg-felg-MP0779-Ab-2; GM-Tg-cang-MP0779-Ab-1/ GM-Tg-cang-MP0779-Ab-2;
GM-Tg-bovg-MP0779-Ab-1/ GM-Tg-bovg-MP0779-Ab-2; GM-Tg-equg-MP0779-Ab-1/ GM-Tg-equg-MP0779-Ab-2
Products NameAnti-LY6G6F monoclonal antibody
Formatmab
Target NameLY6G6F
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LY6G6F benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LY66F/ LY6G6F/ C6orf21 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0779
    Target NameLY6G6F
    Gene ID259215,433099,309609,481715,101100810,100050516
    Gene Symbol and SynonymsC6orf21,G6f,LY6G6,LY6G6D,LY6G6F,NG32
    Uniprot AccessionQ5SQ64,Q6MG56
    Uniprot Entry NameLY66F_HUMAN,LY66F_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000204424
    Target ClassificationN/A

    The target: LY6G6F, gene name: LY6G6F, also named as C6orf21, G6f, LY6G6, LY6G6D, NG32. The human G6f protein is a type I transmembrane protein belonging to the immunoglobin (Ig) superfamily, which is comprised of cell-surface proteins involved in the immune system and cellular recognition (de Vet et al., 2003 [PubMed 12852788]).[supplied by OMIM, Mar 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.